Funding for this research was provided by:
Office of the Secretary of Defense (W81XWH-15-1-0159)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR070254, AR053503)
Jerome L. Greene Foundation (Scholar Award)
Camille Julia Morgan Arthritis Research and Education Fund
Text and Data Mining valid from 2018-03-23
Received: 2 November 2017
Accepted: 1 February 2018
First Online: 23 March 2018
Ethics approval and consent to participate
: The Johns Hopkins Institutional Review Board has approved this study and all participants signed informed consent forms (IRB #: NA-00040493; NA-00071923).
: Not applicable.
: ED previously served on the scientific advisory board for Padlock Therapeutics, Inc., and is an author on licensed Patent No. 8,975,033 entitled “Human Autoantibodies Specific for PAD3 which are Cross-reactive with PAD4 and their Use in the Diagnosis and Treatment of Rheumatoid Arthritis and Related Diseases”. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.